1. **Identification**
   Catalogue code: Y0001994
   Unit Quantity *: ca 10 g

   *The total amount of material (active substance and excipients, if any) which has been filled in each vial or ampoule, for customs purposes. Circa (“ca”) quantity is not to be considered accurate from an analytical point of view.

2. **Scientific Information**

   **2.1 Intended use**
   This leaflet supplements the currently valid European Pharmacopoeia monograph(s) and/or general chapter(s) describing the suitable use of this Reference Standard.


   **Human immunoglobulin for anticomplementary activity BRP** is intended for use as the reference preparation for the test for anticomplementary activity of immunoglobulin (2.6.17) as prescribed in the monograph *Human normal immunoglobulin for intravenous administration (918)*. Each vial contains 10 g of freeze-dried highly purified immunoglobulin G.

   **2.2 Instructions for use**
   Open the original container with precautions to avoid contamination. Wear gloves. Operate under a laminar flow.

   If the BRP is to be re-used, after reconstitution take out the necessary volume to perform the test then re-cap the vial tightly and place it immediately back to +5°C ± 3°C.

   **Human immunoglobulin for anticomplementary activity BRP** serves as negative and positive control. Carry out the test on the immunoglobulin to be examined and on the BRP in parallel.

   - Allow the vial and content to reach room temperature
   - Tap vial gently to collect material at the bottom
   - Using an appropriate sterile syringe reconstitute the reference preparation by injecting 180.4 mL of water R or water for injection. Carefully mix and stir very gently, avoiding foaming, until complete dissolution.
   - Check by visual inspection that complete dissolution has been achieved prior to use. The solution thus obtained contains 50 mg/mL of immunoglobulin G.
   - For the BRP, prepare the incubation mixtures as follows:

     |                  | Negative control | Positive Control |
     |------------------|------------------|-----------------|
     | BRP              | 0.2 mL           | 0.8 mL          |
     | Gelatine barbital buffer solution | 0.6 mL | --             |
     | Complement       | 0.2 mL           | 0.2 mL          |

   - Close the tubes and incubate at 37°C for 60 min.
   - For the negative control, add 0.2 mL of the incubation mixture to 9.8 mL of gelatin barbital buffer solution to dilute the complement
   - For the positive control, add 1.0 mL of the incubation mixture to 9.0 mL of gelatin barbital buffer solution to dilute the complement
Proceed with the test as described in general chapter 2.6.17 to determine the remaining complement activity.

**Validity requirements:** 10-40 per cent consumption of complement for the negative control, 60-100 per cent consumption of complement for the positive control.

The reconstituted BRP may be used as reference preparation for the test of anticomplementary activity of immunoglobulins for a maximum of 14 days after reconstitution if stored under defined validated conditions at +5°C ± 3°C.

**2.3 The Uncertainty of the assigned value**
According to ISO Guide 34 and ISO Guide 35, for this Pharmacopoeial standard the uncertainty of the assigned value is not stated since it is considered to be negligible in relation to the defined limits of the method-specific assays for which the reference standard is used. Please also refer to Ph. Eur. chapter 5.12.

**2.4 Validity**
A statement on the validity of the batch (Batch Validity Statement) can be printed directly from the EDQM website (Reference Standards Database).

**3. Storage conditions**
Store the original container at +5°C ± 3°C. Do not store at lower temperatures. Do not freeze. Once opened, the vial should be used as soon as possible or as stated in section 2.2.

**4. Safety**
Biological preparation for laboratory use only. Handle in accordance with good occupational hygiene, safety and laboratory practices and take precautions to avoid exposure.

**5. Shipping conditions**
Please check shipping conditions on the EDQM website (Reference Standards Database).

**6. Additional information**
Pharmeuropa Bio & Sci Notes is an open-access publication that is freely available on the EDQM website (www.edqm.eu).
EDQM website (Knowledge Database, Reference Standards Database, HelpDesk).

**7. Citation**
Users shall ensure that any reference made to an EDQM Reference Standard in any publication, presentation or public document (ex. scientific articles, data sheets for kits) bears the exact name, and catalogue code of the Reference Standard and the exact name and address of EDQM as given on the first page of this information leaflet.

**8. Warranties, Liability and disputes**

a) **Warranties**
The Council of Europe does not offer any warranty concerning the quality or safety of any item supplied, the absence of any defects, or its fitness for any particular purpose except that of use as a Ph. Eur. CRS, BRP or RS for use as reference standards in tests and assays carried out in accordance with the official methods of the European Pharmacopoeia (Ph. Eur.) by professionals with the necessary technical skills. In particular, the Council of Europe (EDQM) does not guarantee that the items will meet the customer’s specific expectations. The Council of Europe also does not guarantee that the purchase or use of the items will not infringe any intellectual property rights, in particular patents.

The Council of Europe (EDQM) only guarantees that the items meet the above conditions in the moment they are handed over to the carrier being responsible for the delivery of the item to the purchaser and that the carrier and the purchaser have received clear and accurate instructions for the item’s delivery and reception.

No other warranty, either express or implied, is given by the Council of Europe (EDQM).

b) **Liability**
The Council of Europe (EDQM) shall not be liable for the failure to meet the requirements of the legislation of the country where the items are delivered. It is the purchaser’s responsibility to check with the local, regional or national authorities and to make sure that the goods or services that they intend to order may be imported or used in that country. The purchaser is solely responsible for the choice of items, their storage from the time of delivery and their use.
In no event shall the Council of Europe (EDQM) be liable for any damages due to the use of items, including, but not limited to, lost profits, loss of use, costs of procurement of substitute goods, services or systems, or for any indirect, special, incidental, punitive, or consequential damages, however caused and, whether in contract, tort or under any other theory of liability, whether or not the Purchaser has been advised of the possibility of such damage.

c) Disputes
In accordance with the provisions of article 21 of the General Agreement on the Privileges and Immunities of the Council of Europe, all disputes between the Council of Europe (EDQM) and the customer as regards the application of this contract shall be submitted, if a mutual agreement cannot be reached between the parties, to arbitration as laid down in Order No. 481 of the Secretary General, approved by the Committee of Ministers.

9. Adoption
The present reference standard has been officially adopted by the European Pharmacopoeia Commission.

10. Signature
This document is electronically signed by:

Dr Pierre Leveau
Head of the Quality, Safety and Environment Division